Cardiovascular toxicity in paediatric cancer treatment

Steven Lipshultz1,2

1Children’s Hospital of Michigan, Detroit, Michigan, USA,2Wayne State University, Detroit, Michigan, USA


Children with cancer are now living longer due to advances in cancer treatments, but not without consequences. Anthracyclines, chemotherapy agents commonly used to treat solid and hematologic tumours, are associated with persistent and progressive cardiotoxicity. Collaborative efforts between oncologists and cardiologists are currently taking place to balance oncologic efficacy with the risks of cardiotoxicity to maximize the quality of life and survival for long-term survivors of childhood cancer. This presentation describes the epidemiology of cardiotoxicity in childhood cancer survivors, provides the latest evidence in prevention and surveillance, and suggests areas of future research.